Hutchison China MediTech, also known as Chi-Med, has established a robust pipeline of investigational drug candidates, leveraging a comprehensive in-house discovery engine. The company focuses on developing therapies targeting a range of validated and novel molecular targets, including MET, VEGFR, FGFR, and CD47, among others. Their drug candidates are designed to address various cancers and hematological malignancies, with some currently undergoing clinical trials as monotherapies and in combination with other treatment modalities. Chi-Med's commitment to innovation is further exemplified by its collaborations with leading global pharmaceutical companies, enhancing its research and development capabilities.

The company's research and development operations encompass a wide array of scientific disciplines, including chemistry, biology, pharmacology, and toxicology, supported by a growing team of approximately 900 scientists. Chi-Med emphasizes a holistic approach to treating complex diseases, particularly cancer and immunology, by developing highly selective therapies that can be tailored to individual patient needs. Their global development infrastructure, with a significant presence in the U.S. and Europe, aims to bring innovative therapies to patients worldwide, focusing on overcoming drug resistance and improving treatment efficacy through combination therapies and optimized dosing strategies.

China

Chi-Med (Nasdaq/AIM: HCM) is an innovative biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has a portfolio of nine cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China.


Cancer

Digestive System Diseases

Hematologic Diseases

Immune System Diseases

Inflammatory disorders

Kidney Diseases

Lung Diseases

Urogenital Diseases

Hutchison China MediTech / Chi-Med

Colorectal cancer

Gastric cancer

Non-small cell lung carcinoma

Renal cell carcinoma

Savolitinib is an oral, potent, and highly selective small molecule inhibitor of MET, a receptor tyrosine kinase which has been shown to function abnormally in many types of solid tumors promoting tumor growth, angiogenesis, and metastasis.&nbsp; Savolitinib has been studied in over 1,000 patients to date.&nbsp; In clinical studies it has shown promising clinical efficacy in patients with MET gene alterations in multiple tumor types with an acceptable safety profile.

ORPATHYS (Savolitinib)

Metastatic colorectal cancer

Solid tumor/s

Fruquintinib is a highly selective and potent oral inhibitor of vascular endothelial growth factor receptor (“VEGFR”) 1/2/3.&nbsp; VEGFR inhibitors play a pivotal role in blocking tumor angiogenesis.&nbsp; Fruquintinib was designed to improve kinase selectivity to minimize off-target toxicities, improve tolerability and provide more consistent target coverage.&nbsp; The generally good tolerability in patients to date, along with fruquintinib’s low potential for drug-drug interaction based on preclinical assessment, suggests that it may also be highly suitable for combinations with other anti-cancer therapies.
<a href="https://www.chi-med.com/chi-med-initiates-fresco-2-a-global-phase-iii-trial-of-fruquintinib-in-metastatic-crc/">Source</a>

ELUNATE (Fruquintinib) (VEGFR 1/2/3)

Cholangiocarcinoma

Neuroendocrine tumor

Pancreatic cancer

Surufatinib (previously known as HMPL-012 or sulfatinib) is a novel, oral angio-immuno kinase inhibitor that selectively inhibits the tyrosine kinase activity associated with vascular endothelial growth factor receptor (“VEGFR”) and fibroblast growth factor receptor (FGFR), which both inhibit angiogenesis, and colony stimulating factor-1 receptor (CSF-1R), which regulates tumor-associated macrophages, promoting the body’s immune response against tumor cells.&nbsp; Its unique dual mechanism of action may be very suitable for possible combinations with other immunotherapies.&nbsp; Surufatinib is in several late-stage and proof-of-concept clinical trials in China and proof-of-concept clinical trials in the U.S.
VEGFR 1/2/3, FGFR1, CSF-1R inhibitor

SULANDA (Surufatinib) 

Primary immune thrombocytopenia

HMPL-523 is a novel, highly selective and potent small molecule &nbsp;inhibitor for oral administration targeting spleen tyrosine kinase, also &nbsp;known as Syk. Syk is a major component in B-cell receptor signaling and &nbsp;is an established therapeutic target in multiple subtypes of B-cell &nbsp;lymphomas and autoimmune disorders.
<a href="https://www.chi-med.com/chi-med-initiates-a-phase-i-trial-of-hmpl-523-in-patients-with-immune-thrombocytopenia-itp-in-china/">Source</a>

Sovleplenib (HMPL-523) (Syk inhibitor) 

ORPATHYS (Savolitinib) (C-MET inhibitor)

Gastroesophageal adenocarcinomas

ELUNATE (Fruquintinib) + paclitaxel

Acute myeloid leukemia

Blood cancer

Hematologic malignancies

HMPL-306 is a novel dual-inhibitor of IDH1 and IDH2 enzymes. Mutations of IDH1 and IDH2 have been implicated as drivers of certain hematological malignancies, gliomas and solid tumors, particularly among AML patients. Although some IDH inhibitors have been approved in certain markets for AML, isoform switching between the cytoplasmic mutant IDH1 and mitochondrial mutant IDH2 often leads to acquired resistance to single inhibitors of IDH1 or IDH2. Targeting both IDH1 and IDH2 mutations may provide therapeutic benefits in cancer patients by overcoming this acquired resistance.

HMPL-306

ORPATHYS (Savolitinib) + osimertinib

Non-Hodgkin lymphoma

HMPL-689 is a novel, selective oral inhibitor targeting the isoform &nbsp;PI3Kδ, a component in the B-cell receptor signaling pathway. HMPL-689’s &nbsp;pharmacokinetic (“PK”) properties are favorable with good oral &nbsp;absorption, moderate tissue distribution and low clearance in &nbsp;preclinical PK studies, we therefore anticipate low risk of drug &nbsp;accumulation and drug-to-drug interaction.
<a href="https://www.chi-med.com/chi-med-highlights-hmpl-689-clinical-data-to-be-presented-at-the-62nd-ash-annual-meeting/">Source</a>

Amdizalisib (HMPL-689) (PI3K) 

ORPATHYS (Savolitinib) + TAGRISSO

Intrahepatic cholangiocarcinoma

Mesothelioma

HMPL‑453 is a novel, highly selective and potent small molecule inhibitor targeting fibroblast growth factor receptors 1, 2&nbsp;and&nbsp;3.
FGFRs are a sub‑family of receptor tyrosine kinases. Activation of FGFR signaling pathways is central to several biological processes. In normal physiology, FGF/FGFR signaling is involved in embryonic development (organogenesis and morphogenesis), tissue repair, angiogenesis, neuroendocrine and metabolism homeostasis. Given its complexity and critical role in a number of important physiological processes, aberrant FGFR signaling has been found to be a driving force in tumor growth, promotion of angiogenesis, as well as conferring resistance to anti‑tumor therapies.

HMPL-453 (FGFR 1/2/3)

Follicular lymphoma

Tazemetostat

Kidney cancer

About Fruquintinib and Second-line treatment of RCC
Fruquintinib is a selective oral inhibitor of vascular endothelial growth factor receptors (“VEGFR”) -1, -2 and -3. VEGFR inhibitors play a pivotal role in blocking tumor angiogenesis. Fruquintinib was designed to have enhanced selectivity that limits off-target kinase activity, allowing for high drug exposure, sustained target inhibition, and flexibility for the potential use as part of combination therapy. Fruquintinib has demonstrated a manageable safety profile and is being investigated in combination with other anti-cancer therapies including the approved PD-1 inhibitor, sintilimab.

ELUNATE (Fruquintinib) + Sintilimab

Warm autoimmune hemolytic anemia

Sovleplenib (HMPL-523) (Syk inhibitor)

Pancreatic ductal adenocarcinoma

Surufatinib (previously known as HMPL-012 or sulfatinib) is a novel, oral angio-immuno kinase inhibitor that selectively inhibits the tyrosine kinase activity associated with vascular endothelial growth factor receptor (“VEGFR”) and fibroblast growth factor receptor (FGFR), which both inhibit angiogenesis, and colony stimulating factor-1 receptor (CSF-1R), which regulates tumor-associated macrophages, promoting the body’s immune response against tumor cells.&nbsp; Its unique dual mechanism of action may be very suitable for possible combinations with other immunotherapies.&nbsp; Surufatinib is in several late-stage and proof-of-concept clinical trials in China and proof-of-concept clinical trials in the U.S.
 
Camrelizumab (SHR-1210) is a humanized monoclonal antibody targeting the programmed death-1 (PD-1) receptor. Blockade of the PD-1/PD-L1 signaling pathway is a therapeutic strategy showing success in a wide variety of solid and hematological cancers. Currently, more than 10 clinical trials are underway worldwide in a broad range of tumors&nbsp; and treatment settings.

SULANDA (Surufatinib) + Camrelizumab

Endometrial cancer

Fruquintinib is a highly selective and potent oral inhibitor of &nbsp;VEGFR-1, -2 and -3. VEGFR inhibitors play a pivotal role in blocking &nbsp;tumor angiogenesis. Fruquintinib was designed to improve kinase &nbsp;selectivity to minimize off-target toxicities, improve tolerability and &nbsp;provide more consistent target coverage. The generally good tolerability &nbsp;in patients to date, along with fruquintinib’s low potential for &nbsp;drug-drug interaction based on preclinical assessment, suggests that it &nbsp;may also be highly suitable for combinations with other anti-cancer &nbsp;therapies.
<a href="https://www.hutch-med.com/fruquintinib-tislelizumab-phase-ib-ii-in-tnbc-or-ec/">Source</a>

Leukemia

HMPL-506

Small Molecule Pharmaceuticals

Therapeutic

Hutchison China MediTech / Chi-Med

Company Details